UNSPSC 51384101: Fenbufen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9815R1WR9B, chemically known as propionic acid, 3-(4-biphenylylcarbonyl)- but generally known as fenbufen, which bears US NIH Compound Identifier 3335. European Medicines Agency schedules Fenbufen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07543MIG. The term FENBUFEN is an International Non-Proprietary Name.

UNSPSC 51384101 Fenbufen is a Commodity code that covers individual pharmaceutical active ingredients and finished pharmaceutical products procured by state and local health agencies, but recent state and local solicitations show minimal activity specifically under this code. The three most recent opportunities tagged to this code involve naloxone (an opioid antagonist), direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through cooperative purchasing—none of which are fenbufen-specific procurements. State and local governments acquire pharmaceuticals through county health departments, state HHS commissions, and multistate cooperative purchasing alliances, typically via IFB, RFI, and RFP mechanisms that bundle multiple drug products rather than single-agent acquisitions. The issuing bodies include Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which administers purchases across multiple participating states including Oregon.

Recent activity shows Seminole County issuing an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives; the Texas HHS Commission posting an RFI (HHS0017013, April 3, 2026) on direct-to-manufacturer prescription programs to inform future contracting strategy; and MMCAP posting an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local facilities. The code shows little evidence of active fenbufen-specific procurement at the state and local level in the current market. The mismatch between the code's nominal scope (fenbufen, a nonsteroidal anti-inflammatory drug) and the naloxone, general pharmaceutical, and prescription-program opportunities present suggests either miscoding in state procurement systems or minimal recent fenbufen demand among state and local health agencies.